

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pure peptide consisting of ~~an~~ the amino acid sequence of SEQ ID NO.1.
2. (Canceled)
3. (Previously Presented) The peptide of Claim 1, wherein said peptide reduces the symptoms of a viral disease.
4. (Previously Presented) The peptide of Claim 3, wherein said viral disease is hepatitis B infection.
5. (Previously Presented) The peptide of Claim 1, wherein said peptide has immuno-stimulating properties.
6. (Canceled)
7. (Canceled)
8. (Currently Amended) A pharmaceutical composition comprising a pure peptide consisting of ~~an~~ the amino acid sequence of SEQ ID NO.1.
9. (Canceled)
10. (Currently Amended) A method of making a pharmaceutical composition comprising providing a pure peptide consisting of ~~an~~ the amino acid sequence of SEQ ID NO.1; and admixing said peptide with a pharmaceutically acceptable carrier.
11. (Currently Amended) A method of reducing the effects of a human disease comprising administering a pharmaceutically effective dose of a pure peptide consisting of ~~an~~ the amino acid sequence of SEQ ID NO.1
12. (Previously Presented) The method of Claim 11, wherein said human suffers from a viral disease.
13. (Previously Presented) The method of Claim 12, wherein said viral disease is hepatitis B infection.
14. (Currently Amended) A method of stimulating the immune system of an individual comprising administering a pharmaceutically effective dose of a pure peptide consisting of ~~an~~ the amino acid sequence of SEQ ID NO.1
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)

19. (Canceled)
20. (Canceled)
21. (Previously Presented) The method of claim 14, wherein said peptide is administered with a food supplement.
22. (Currently Amended) The method of claim 21, wherein said peptide is administered as a nutritional formulation further comprising a pharmaceutically effective dose of a pure peptide consisting of the amino acid sequence of SEQ ID NO.1 admixed with a pharmaceutically or biologically acceptable carrier.
23. (Previously Presented) The method of claim 11, wherein said peptide is administered intravenously, intraarterially, intramuscularly, topically, intracutaneously, subcutaneously, intradermally, transdermally, orally or by inhalation.
24. (Previously Presented) The method of claim 14, wherein said peptide is administered intravenously, intraarterially, intramuscularly, topically, intracutaneously, subcutaneously, intradermally, transdermally, orally or by inhalation.